{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:29:54Z","timestamp":1760059794109,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Neuromyelitis optica (NMO) is a chronic demyelinating inflammatory disease of the central nervous system (CNS), mediated by autoantibodies against aquaporin-4 (AQ4) receptors. In the spectrum of NMO, other autoimmune diseases also coexist, though their association with systemic lupus erythematosus (SLE) is rare. Case Presentation: We present two cases of patients in their 70s who were diagnosed with NMO in the context of SLE. The first case concerns a 78-year-old woman with drug-induced SLE and thoracic myelitis who developed T4-level incomplete paraplegia over three weeks. The second case involves a 71-year-old woman with a history of SLE and myasthenia gravis, presenting with cervical myelitis with progressive worsening of walking and C4-level paraparesis over two months. In both cases, elevated serum anti-AQ4 titers were detected, establishing the diagnosis of NMO and differentiation from an atypical manifestation of SLE-related myelitis. High doses of intravenous corticosteroids with gradual tapering, along with cyclophosphamide, followed by rituximab, were administered in both patients. The first patient showed a poor response, while the second showed improvement. Conclusions: The coexistence of NMO with SLE is rare, but the occurrence of myelitis in patients with connective tissue diseases should raise the suspicion of NMO, especially in elderly women and several years after the diagnosis of SLE. Time to treatment is critical, as delays in treating NMO can result in cumulative and disabling damage.<\/jats:p>","DOI":"10.3390\/reports8030110","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T10:46:05Z","timestamp":1752662765000},"page":"110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuromyelitis Optica Diagnosis in Two Elderly Patients with Systematic Lupus Erythematosus: A Case Series"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-116X","authenticated-orcid":false,"given":"Kyriaki","family":"Astara","sequence":"first","affiliation":[{"name":"Department of Neurology, Army Share Fund Nursing Institution (NIMTS), 11521 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-6454","authenticated-orcid":false,"given":"Maria","family":"Lypiridou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Army Share Fund Nursing Institution (NIMTS), 11521 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7711-5194","authenticated-orcid":false,"given":"Konstantinos","family":"Kalafatakis","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Athens \u201cPammakaristos\u201d, 11144 Athens, Greece"},{"name":"Human Computer Interaction Laboratory, University of Ioannina, 47150 Arta, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Nikolaou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Army Share Fund Nursing Institution (NIMTS), 11521 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Stouraitis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Army Share Fund Nursing Institution (NIMTS), 11521 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis Optica Spectrum Disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16005","DOI":"10.1038\/scsandc.2016.5","article-title":"Myelitis in Systemic Lupus Erythematosus: Clinical Features, Immunological Profile and Magnetic Resonance Imaging of Five Cases","volume":"2","author":"Hryb","year":"2016","journal-title":"Spinal Cord. Ser. Cases"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 EULAR\/ACR Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/BOR.0000000000000522","article-title":"Drug-Induced Lupus Erythematosus: An Update on Drugs and Mechanisms","volume":"30","author":"He","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.autrev.2018.03.016","article-title":"Drug-Induced Lupus: Traditional and New Concepts","volume":"17","author":"Vaglio","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome Prediction Models in AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102522","DOI":"10.1016\/j.msard.2020.102522","article-title":"Risk of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder: Recognition and Preventive Strategy","volume":"46","author":"Ma","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/09612033231191180","article-title":"Overlap Syndrome of Anti-Aquaporin-4 Positive Neuromyelitis Optica Spectrum Disorder and Systemic Lupus Erythematosus: A Systematic Review of Individual Patient Data","volume":"32","author":"Kopp","year":"2023","journal-title":"Lupus"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wright, S.K., Wassmer, E., and Vincent, A. (2021). Pathogenic Antibodies to AQP4: Neuromyelitis Optica Spectrum Disorder (NMOSD). Biochim. Et. Biophys. Acta (BBA)-Biomembr., 1863.","DOI":"10.1016\/j.bbamem.2021.183772"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised Diagnostic Criteria for Neuromyelitis Optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17562864211056710","DOI":"10.1177\/17562864211056710","article-title":"Adverse Events of Rituximab in Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis","volume":"14","author":"Wang","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gao, F., Chai, B., Gu, C., Wu, R., Dong, T., Yao, Y., and Zhang, Y. (2019). Effectiveness of Rituximab in Neuromyelitis Optica: A Meta-Analysis. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1261-2"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jocn.2015.08.033","article-title":"Rapid Exacerbation of Neuromyelitis Optica after Rituximab Treatment","volume":"26","author":"Dai","year":"2016","journal-title":"J. Clin. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jamaneurol.2013.3583","article-title":"Individualized Rituximab Treatment for Neuromyelitis Optica Spectrum Disorders","volume":"70","author":"McKeon","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Aspden, J.W., Murphy, M.A., Kashlan, R.D., Xiong, Y., Poznansky, M.C., and S\u00eerbulescu, R.F. (2023). Intruders or Protectors-the Multifaceted Role of B Cells in CNS Disorders. Front. Cell Neurosci., 17.","DOI":"10.3389\/fncel.2023.1329823"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","article-title":"Targeting the Complement System in Neuromyelitis Optica Spectrum Disorder","volume":"21","author":"Asavapanumas","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"105062","DOI":"10.1016\/j.msard.2023.105062","article-title":"Tocilizumab Treatment in Neuromyelitis Optica Spectrum Disorders: Updated Meta-Analysis of Efficacy and Safety","volume":"80","author":"Wang","year":"2023","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/3\/110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:10:30Z","timestamp":1760033430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/3\/110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["reports8030110"],"URL":"https:\/\/doi.org\/10.3390\/reports8030110","relation":{},"ISSN":["2571-841X"],"issn-type":[{"type":"electronic","value":"2571-841X"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}